The EPS projection of Array BioPharma Inc. (NASDAQ:ARRY) for period quarter completed 2016-12-31 is $-0.21.
The EPS estimates pronounced a week and 30 days ago were $-0.21 and $-0.21 correspondingly. The EPS forecasts specified 60 and 90 days before were $-0.21 and $-0.21 respectively. From a week ago, the aberration in EPS forecast is 0.03 percent.
The mean EPS prediction straightaway before the earnings release for the quarter completed 4 is $-0.21 based on 6 EPS estimations. The EPS stated on 2016-08-04 was $-0.17. The EPS surprise was $-0.02, or -13.33 percent. The standard deviation as per known EPS estimates was $0.13.
The positive EPS revisions were 1 a week earlier and negative revisions were 0. In last 30 and 60 days, the positive EPS revisions were 1 and 0 correspondingly, while for 90 and 120 days, revisions count was 0 and 0.
The negative revisions of per-share earnings in the last 30 and 60-days were 0 and 0 in that order. however, for 90 and 120 days’ period, the count was 1 and 1 in that order.
EPS revisions upgrade and downgrade in the last 18 days were 0 and 0 correspondingly.
Quarterly Sales Estimates
The arithmetic mean of probable annual sales of Array BioPharma Inc. (NASDAQ:ARRY) is $40.82 and the median was $43.15. The estimate is stated by 3 analysts for the fiscal 2017.
The highest annual projection is $58.71 and lowest sales target is $20.6. This marks a standard deviation of $19.161.
Almost 3 have given revised positive sales forecast in the past week and 3 have downgraded forecasts. As per the stated estimates, the change in target from the past week is -27.521 percent.
Nearly 3 have revised sales projections in positive side over the past month and 3 have downgraded forecasts. This shows a mean estimate deviation of -27.521 percent.
Just about 3 have revised sales forecast on plus side over the quarter and 3 have downgraded forecasts. This shows mean estimate deviation of 69.237 percent.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...